"Dexamethasone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-inflammatory 9-fluoro-glucocorticoid.
| Descriptor ID |
D003907
|
| MeSH Number(s) |
D04.210.500.745.432.769.344 D04.210.500.908.238
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dexamethasone".
Below are MeSH descriptors whose meaning is more specific than "Dexamethasone".
This graph shows the total number of publications written about "Dexamethasone" by people in this website by year, and whether "Dexamethasone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 4 | 4 | 8 |
| 1995 | 2 | 1 | 3 |
| 1996 | 2 | 4 | 6 |
| 1997 | 3 | 1 | 4 |
| 1998 | 2 | 0 | 2 |
| 1999 | 0 | 2 | 2 |
| 2000 | 2 | 3 | 5 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 3 | 4 |
| 2003 | 4 | 1 | 5 |
| 2004 | 1 | 5 | 6 |
| 2005 | 1 | 1 | 2 |
| 2006 | 4 | 3 | 7 |
| 2007 | 4 | 0 | 4 |
| 2008 | 1 | 2 | 3 |
| 2009 | 4 | 2 | 6 |
| 2010 | 2 | 3 | 5 |
| 2011 | 6 | 3 | 9 |
| 2012 | 2 | 5 | 7 |
| 2013 | 1 | 6 | 7 |
| 2014 | 5 | 4 | 9 |
| 2015 | 6 | 4 | 10 |
| 2016 | 2 | 11 | 13 |
| 2017 | 4 | 3 | 7 |
| 2018 | 3 | 5 | 8 |
| 2019 | 2 | 5 | 7 |
| 2020 | 2 | 5 | 7 |
| 2021 | 4 | 3 | 7 |
| 2022 | 0 | 6 | 6 |
| 2023 | 0 | 11 | 11 |
| 2024 | 4 | 3 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dexamethasone" by people in Profiles.
-
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma. Blood. 2024 08 29; 144(9):955-963.
-
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. Blood Cancer J. 2024 07 08; 14(1):107.
-
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024 05 29; 14(1):87.
-
Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone. Pol Arch Intern Med. 2024 05 28; 134(5).
-
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk. Blood Cancer J. 2024 04 22; 14(1):69.
-
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN. Am J Hematol. 2024 07; 99(7):1257-1268.
-
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study. Br J Haematol. 2024 Jun; 204(6):2227-2232.
-
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2023 Dec 18; 32(1):36.
-
Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. Clin Cancer Res. 2023 12 01; 29(23):4784-4796.
-
Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma. Blood Adv. 2023 10 10; 7(19):5703-5712.